| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 2 | +565K | 100% | $3.20 | +$1.81M |
| Sells | 0 | ||||
| Net | +2 | +565K | 100% | +$1.81M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 10%+ Owner | $5.2M | +$1.77M | +51.7% | Dec 23, 2024 |
| Steve Elms | Director | $1.05M | +$35.5K | +3.49% | Feb 12, 2025 |
| Peter L. Hoang | President and CEO, Director | $234K | Mar 24, 2022 | ||
| Anthony H. Kim | Chief Financial Officer | $55.5K | Mar 24, 2022 | ||
| Frederick G. Wasserman | Director | $31.6K | Jun 8, 2021 | ||
| David Laskow-Pooley | Director | $26.8K | May 24, 2022 | ||
| Katharine Knobil | Director | Feb 12, 2025 | |||
| Eliot M. Lurier | Interim CFO | Jun 30, 2023 | |||
| Nadia Agopyan | SVP, Regulatory Affairs | Feb 27, 2023 | |||
| Gerald Garrett | Vice President, Clinical Ops. | Feb 17, 2022 | |||
| John Robert Wilson | Director | Jun 6, 2023 | |||
| Juan Vera | President and CEO, Director | Feb 12, 2025 | |||
| Michael Loiacono | Chief Accounting Officer | Feb 27, 2023 | |||
| Anna Szymanska | Vice President, Quality | Feb 27, 2023 | |||
| Norman David Eansor | Director | Feb 12, 2025 | |||
| Tsvetelina P. Hoang | VP, Research and Development | Feb 27, 2023 | |||
| Mythili Koneru | Chief Medical Officer | Feb 27, 2023 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|